RECRUITING

Preventing Alzheimer's With Cognitive Training

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Dementia is the most expensive medical condition in the US and increases in prevalence with age. More than 5 million Americans have Alzheimer's disease, the most common form of dementia. Mild cognitive impairment is a transitional stage between normal cognitive aging and Alzheimer's disease or another type of dementia, and is indicative of higher risk for dementia. In addition to the obvious health and quality-of-life ramifications of dementia, there are high direct (e.g., subsidizing residential care needs) and indirect (e.g., lost productivity of family caregivers) economic costs. Implementing interventions to prevent MCI and dementia among older adults is of critical importance to health and maintained quality-of-life for millions of Americans. Recent data analyses from the Advanced Cognitive Training in Vital Elderly study (ACTIVE) indicate that a specific cognitive intervention, speed of processing training (SPT), significantly delays the incidence of cognitive impairment across 10 years. The primary contribution of the proposed research will be the determination of whether this cognitive training technique successfully delays the onset of clinically defined MCI or dementia across three years.

Official Title

Cognitive Training to Reduce Incidence of Cognitive Impairment in Older Adults

Quick Facts

Study Start:2019-02-19
Study Completion:2026-01-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT03848312

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:65 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Be age 65 or older at time of consent
  2. * Have ability to speak and understand English or Spanish
  3. * Report adequate sensorimotor capacity to perform the computer exercises
  4. * Report adequate visual capacity to read from a computer screen at a typical viewing distance
  5. * Show adequate auditory capacity to understand conversational speech
  6. * Show adequate motor capacity to touch a computer screen or control a computer mouse.
  7. * Have no evidence of Mild Cognitive Impairment (MCI) or dementia, as assessed by the Montreal Cognitive Assessment score \>=26.
  8. * Have adequate mental health (no self-reported diagnoses of mental illness that would interfere with ability to comply with study procedures or benefit from intervention)
  9. * Wiling to complete all study activities
  10. * Ability to understand study procedures and comply with them for the length of the study
  1. * Currently enrolled in another randomized clinical trial, treatment trial, or another research study that assesses cognition
  2. * Previous participation in a cognitive training study
  3. * Self-reported vision, hearing, or motor difficulties that would interfere with the ability to complete the study interventions
  4. * Self-reported diagnosis of mild cognitive impairment, dementia, stroke, traumatic brain injury, brain tumor, or a neurological disorder that affects cognition or would interfere with the ability to benefit from the study intervention (e.g., Parkinson disease, multiple sclerosis), or any other unstable medical conditions that is predisposing to imminent cognitive or functional decline (e.g., congestive heart failure, chronic obstructive pulmonary disorder dependent on oxygen, or undergoing chemotherapy or radiation).
  5. * Self-reported use of medications typically prescribed for dementia such as: Namenda, Memantine, Namzaric, Donepezil, Aricept, Rivastigmine, Exelon, Razadyne, Galantamine, Reminyl, aducanumab, Aduhlem.
  6. * Completion of 10 or more hours of a computerized cognitive training program in the last 5 years such as: Lumosity, Posit Science Brain Fitness, InSight, or Brain HQ, Lace, CogMed, CogniFit, Happy Neuron, Elevate, or Dakim
  7. * Severe depressive symptoms (Geriatric Depression Scale score \>=5)

Contacts and Locations

Study Contact

Jennifer L O'Brien, PhD
CONTACT
727-873-4415
jenobrien@usf.edu
Jennifer Lister, PhD
CONTACT
813-974-9712
jlister@usf.edu

Study Locations (Sites)

University of Florida
Gainesville, Florida, 32611
United States
University of Florida
Jacksonville, Florida, 32209
United States
University of North Florida
Jacksonville, Florida, 32224
United States
The Roskamp Institute
Sarasota, Florida, 34243
United States
University of South Florida
Tampa, Florida, 33620
United States
Duke Health
Durham, North Carolina, 27705
United States
Clemson University Institute for Engaged Aging
Seneca, South Carolina, 29672
United States

Collaborators and Investigators

Sponsor: University of South Florida

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2019-02-19
Study Completion Date2026-01-31

Study Record Updates

Study Start Date2019-02-19
Study Completion Date2026-01-31

Terms related to this study

Additional Relevant MeSH Terms

  • Age-related Cognitive Decline
  • Alzheimer's Disease and Related Dementias